Drugs / CD19.28ζ-CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01593696 | Jun 2012 → Nov 2016 | large B-cell lymphoma, leukemia, non-Hodgkin lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19.28ζ-CAR T cells | “We conducted a phase I trial of autologous CD19.28ζ-CAR T cells in CAYAs with relapsed or refractory B-ALL.” PMID 33764809 ↗ Mar 2021 |
| Action | Deplete | “anti-CD19-CAR-transduced T cells show robust killing” NCT01593696 ↗ |
| Modality | Cell therapy | “CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity” PMID 25319501 ↗ Oct 2014 |
| Route | Intravenous | “The previously determined maximum tolerated dose (MTD) of 1 X 10(6) will be administered intravenously.” NCT01593696 ↗ |